Investors keen to put money into AMR SMEsInvestments into new drugs to tackle antimicrobial resistance (AMR) are set to boost the participation of SMEs. At the 11th Berlin Conference on Life Sciences, two new financing initiatives, which focus … more ➔
Santhera’s idebenone not efficient in PPMS patientsSwiss Santhera Pharmaceuticals EU-approved LHON treatment Raxone (idebenone) has failed to show clinical efficacy in another indication: After US and EU regulators rejected an extension of market approval … more ➔
Inhaled IL-4 halts neuron destruction in MS models An US-German team has found a way to halt the inflammatory brain cell destruction in mice with multiple sclerosis (MS) without suppression of the human immune system. more ➔
Convert Pharmaceuticals SA closes €13.6m Series A round Liège-based Convert Pharmaceuticals SA has been granted a total of €13.6m in equity and non-dilutive funding by investors Droia Oncology Ventures, Meusinvest and Spinventure, with non-dilutive … more ➔
Novo Holdings launches €135m fund to combat antimicrobial resistanceNovo Holdings has launched the REPAIR impact fund commissioned by the Novo Nordisk Foundation. The goal is to invest into early-stage drug developers with new concepts to fight antimicrobial … more ➔
Bavarian Nordic and AZ combine cancer jab with durvalumab AstraZeneca (AZ) and Bavarian Nordic (BN) combine BN’s cancer vaccine CV301 and AZ’s PD-L1 checkpoint blocker durvalumab in an investigator-sponsored trail to check synergistic effects in patients with … more ➔
EMA recommends two orphan drugs for approvalThe European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended three medicines, two thereof orphan drugs, at its February 2018 meeting. more ➔
Bioeconomy: Bringing in the publicEverybody wants green production. Bioeconomy progress, however, must become more visible to consumers and let the civil society get involved to ensure socially robust innovation and perception, according … more ➔
New Screening method for Antibiotic Discovery Pipeline A new method that determines the mode of action underlying antimicrobial compounds could help overcome a major stumbling block in the ongoing effort to discover new antibiotics. Using it, reseachers … more ➔
Cullinan Oncology partners with MAB DiscoveryVirtual oncology company Cullinan Oncology, LLC has selecteed monoclonal antibody provider MAB Discovery GmbH (Neuried) to develop the first candidate of a target portfolio of 8-10 novel … more ➔
